Literature DB >> 15653657

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

Stanislas Pauwels1, Raffaella Barone, Stéphan Walrand, Françoise Borson-Chazot, Roelf Valkema, Larry K Kvols, Eric P Krenning, François Jamar.   

Abstract

The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653657

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  51 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  Method for Fast CT/SPECT-Based 3D Monte Carlo Absorbed Dose Computations in Internal Emitter Therapy.

Authors:  S J Wilderman; Y K Dewaraja
Journal:  IEEE Trans Nucl Sci       Date:  2007-02-17       Impact factor: 1.679

3.  Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

Authors:  Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12       Impact factor: 9.236

Review 4.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

Review 5.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

6.  Is bone marrow uptake of ⁸⁶Y-DOTATOC routinely observed?

Authors:  Stephan Walrand; Stanislas Pauwels; François Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

7.  Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.

Authors:  Youngho Seo; Yoonsuk Huh; Shih-Ying Huang; J Miguel Hernandez-Pampaloni; Randall A Hawkins; W Clay Gustafson; Kieuhoa T Vo; Katherine K Matthay
Journal:  Med Phys       Date:  2019-03-12       Impact factor: 4.071

Review 8.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

9.  Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.

Authors:  Vikas Prasad; Lisa Bodei; Mark Kidd; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10       Impact factor: 9.236

10.  A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.

Authors:  Eric W Price; Kimberly J Edwards; Kathryn E Carnazza; Sean D Carlin; Brian M Zeglis; Michael J Adam; Chris Orvig; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2016-06-28       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.